Evaluation of the therapeutic potential of masitinib and expression of its specific targets c‐Kit, PDGFR‐α, PDGFR‐β, and Lyn in canine prostate cancer cell lines

Canine prostate cancer is classified into adenocarcinoma, transitional cell carcinoma with prostatic involvement, and mixed forms. Early metastatic spread leads to poor prognosis and limited treatment options. Masitinib is approved for the treatment of canine mast cell tumours and inhibits tyrosine...

Full description

Bibliographic Details

Published in:	Veterinary & comparative oncology Vol. 20; no. 3; pp. 641 - 652
Main Authors:	Klose, Katharina, Packeiser, Eva‐Maria, Granados‐Soler, José‐Luis, Hewicker‐Trautwein, Marion, Murua Escobar, Hugo, Nolte, Ingo
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-09-2022
Subjects:	canine masitinib prostate cancer TKI tyrosine kinase prostate cancer canine masitinib TKI tyrosine kinase
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!